Another phase II trial using AZD9150 in advanced solid tumors including metastatic HNSCC as a monotherapy or combined with MED14736/Durvalumab immunotherapy (anti-PD-L1) is currently underway (ClinicalTrials.gov #NCT02499328) (Table 1). The gene discussed is CD274; the disease is head and neck squamous cell carcinoma.